AQR Capital Management LLC Boosts Stake in United Therapeutics Corporation $UTHR

AQR Capital Management LLC grew its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 40.1% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,273,161 shares of the biotechnology company’s stock after buying an additional 364,713 shares during the period. AQR Capital Management LLC owned 2.82% of United Therapeutics worth $362,876,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. F m Investments LLC boosted its stake in shares of United Therapeutics by 1.3% during the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock valued at $741,000 after acquiring an additional 33 shares during the last quarter. HB Wealth Management LLC lifted its holdings in United Therapeutics by 2.9% in the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 35 shares in the last quarter. Park Avenue Securities LLC boosted its stake in shares of United Therapeutics by 1.7% during the 2nd quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock worth $676,000 after purchasing an additional 39 shares during the last quarter. First Financial Bankshares Inc grew its holdings in shares of United Therapeutics by 0.3% during the first quarter. First Financial Bankshares Inc now owns 13,769 shares of the biotechnology company’s stock worth $4,245,000 after buying an additional 42 shares in the last quarter. Finally, Nissay Asset Management Corp Japan ADV grew its holdings in shares of United Therapeutics by 0.8% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 5,235 shares of the biotechnology company’s stock worth $1,614,000 after buying an additional 43 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Trading Up 1.1%

UTHR stock opened at $493.99 on Friday. The company has a market cap of $21.27 billion, a PE ratio of 18.72, a price-to-earnings-growth ratio of 4.85 and a beta of 0.86. The stock has a 50-day moving average price of $457.81 and a two-hundred day moving average price of $374.01. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $496.73.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $6.89 by $0.27. The business had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company’s revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the company posted $6.39 EPS. Equities analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on UTHR shares. Oppenheimer raised their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. UBS Group increased their price target on United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Morgan Stanley set a $447.00 price objective on United Therapeutics in a report on Wednesday, October 29th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a research report on Wednesday, November 19th. Finally, HC Wainwright increased their target price on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $505.00.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $416.35, for a total value of $9,367,875.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 634,537 shares of company stock worth $285,123,273 over the last 90 days. Insiders own 10.30% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.